PFE
PFE
Indicative, may be delayed. Not trading-grade data.
Recently viewed
Only on this browser · up to 5Ticker detail
PFE
Cached quote, historical USD prices, and attributed headlines.
AI-generated
AI overview
Latest PFE headlines
- Pfizer reached a 52-week high, prompting analysis on whether its turnaround is genuine [2]. - A $250,000 investment in Pfizer, Merck, UnitedHealth, and AbbVie could generate $8,000 annually in dividends [4]. - Pfizer is included among AI healthcare stocks for November 2026 [1].
Generated Nov 01, 2026 · 10:58 UTC
- Our Pick Of The Best AI Healthcare Stocks In November 2026 — Yahoo Finance
- Pfizer Just Hit a 52-Week High. Is the Turnaround Finally Real? — Yahoo Finance
- BridgeBio's Heart Disorder Drug Attruby Faces Unanticipated Near-Term Tailwinds, UBS Says — Yahoo Finance
- $250,000 in Merck, Pfizer, UnitedHealth and AbbVie Could Pay $8,000 a Year in Dividends — Yahoo Finance
- Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market Report 2026 | Capitalize on $11.91B Market as Novartis, Voyager and Affinia Accelerate Engineered Capsids — Yahoo Finance
Summary of the linked headlines, not full-article analysis. AI can make mistakes; verify the sources. Not investment advice.
Historical price
23 observations · USD · Source: Yahoo Finance · Sep 30, 2026 · 13:30 UTC to Oct 30, 2026 · 13:30 UTC · latest observation may be incomplete.
News about PFE
- Our Pick Of The Best AI Healthcare Stocks In November 2026 ↗
- Pfizer Just Hit a 52-Week High. Is the Turnaround Finally Real? ↗
- BridgeBio's Heart Disorder Drug Attruby Faces Unanticipated Near-Term Tailwinds, UBS Says ↗
- $250,000 in Merck, Pfizer, UnitedHealth and AbbVie Could Pay $8,000 a Year in Dividends ↗
- Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market Report 2026 | Capitalize on $11.91B Market as Novartis, Voyager and Affinia Accelerate Engineered Capsids ↗
- Pfizer Yields Nearly 6%, but Its Dividend Exceeds Free Cash Flow. Is It Safe? ↗
- HALO Gears Up to Report Q3 Earnings: Is a Beat in the Cards? ↗
- Are Wall Street Analysts Predicting Pfizer’s Stock Will Climb or Sink? ↗
- What Sent Eli Lilly Stock Higher? ↗
- Has The Story Under Johnson & Johnson Stock Run Out? ↗
- How Investors May Respond To Pfizer (PFE) Phase 3 Cancer Trial Win ↗
- What Is Behind Liquidia's Lead Over Its Industry? ↗
- Alnylam Sinks 19% as It Expands Nucresiran Heart Trial Again, Citing “A High Level of Conviction” ↗
- Looking for income? These dividend stocks have high yields that seem well supported. ↗
- Preclinical CRO - Global Market Size, Share, Trends, and Growth Forecasts, 2026-2031 | AI Adoption and Outsourcing Propel Revenue to USD 11.74 Billion ↗
- Global HER2 Targeted Therapies Market Report 2026 | Capitalize on 8.6% CAGR as Pfizer, Roche, AstraZeneca, and Daiichi Sankyo Advance ADCs and Precision Oncology ↗
- GSK vs. Moderna: Which Large-Cap Biotech Stock Offers More Growth? ↗
- Merck Rises 5% as Earnings Beat Lifts Profit Outlook; Eli Lilly Climbs 7%, Johnson & Johnson Edges Higher ↗
- Edison Scientific Announces Agreement with Pfizer to Accelerate Research and Development ↗
- BMY Q3 Earnings Tops Estimates, Higher Charges Weigh on Outlook ↗
Comments and bookmarks
Comments are plain text from NPDev accounts. Bookmarks stay private to the account that saved them.
No comments yet. Be the first to say something.
Sign in to join the conversation.